ArticleCurrent problems in diagnostic radiology
Differentiation of MPNSTs from benign neurofibromas in neurofibromatosis patients using ADC and SUV biomarkers in children and young adults.
Article in Current problems in diagnostic radiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThis study evaluated the sensitivity and specificity of the apparent diffusion coefficient (ADC) and standardized uptake value (SUV) to differentiate malignant peripheral nerve sheath tumors (MPNSTs) from benign neurofibromas in children and young adults with NF1.
methodsWe included 31 patients (19 male, 12 female, age 1-24 years) with 33 nerve sheath tumors, including 11 MPNSTs and 22 benign neurofibromas underwent MRI with diffusion-weighted imaging (DWI, n = 30 lesions, 22 benign, 8 malignant) or 18F-FDG PET (n= 22 lesions, 11 benign, 11 malignant). Tumor apparent diffusion coefficients (ADCmean, ADCmin, and ADCmax) and standardized uptake values (SUVmax) were compared between benign and malignant lesions using Wilcoxon rank-sum tests. In addition, ROC curves were generated to determine optimal cutoffs for each parameter and their respective area under the curve (AUC), sensitivity and specificity. We used Spearman's rank correlation to assess the correlation between ADCmin and SUVmax.
resultsMean ADCmin and ADCmean were significantly lower in MPNST compared to benign neurofibromas (p<0.001). Mean SUVmax was significantly higher in MPNSTs (11.05±4.80) compared to benign lesions (2.21±0.68, p<0.001). An ADCmin cutoff of 1.1×10⁻³ mm²/s differentiated MPNST from benign neurofibromas with a sensitivity of 87%, specificity of 100%, and AUC of 0.97. A SUVmax threshold of 4.9 yielded a sensitivity of 91%, specificity of 100%, and AUC of 0.99. ADCmin correlated inversely with SUVmax (rho= -0.81, p < 0.0001). Longitudinal clustered regression showed progressive declines in ADCmean, ADCmax, and ADCmin in benign neurofibromas, with significant reductions in ADCmean and ADCmax at 2 and 3 years and in ADCmin at 3 years relative to baseline.
conclusionEither ADC metrics or SUVmax could differentiate MPNSTs from benign neurofibromas in children and young adults with high sensitivity and specificity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.